The RCg2 promoter was identified in a search for root-specific genes to combat the rice water weevil (RWW) but expressed at low frequency (~10%). Spatial expression of RCg2 was investigated using two reporter constructs YXA (RCg2-gus-ocs) and YXB (RCg2-gus-RCg2) that included 1.6 kb of the RCg2 5' sequence fused to the ?-glucuronidase (gus) coding region. YXB plants were generated via Agrobacterium-mediated transformation but only 8 of 158 plants analyzed showed strong GUS activity despite the presence of an intact construct. Reactivation of RCg2 gene in rice was investigated by treatment of R0 and R1 of YXB transgenic plants with 5-azacytidine. Reactivation of RCg2-gus was observed in some transgenic plants indicating different mechanisms involved in the gene silencing of the YXB lines. DNA methylation analysis, northern blotting, RT-PCR and small RNA analysis supported the conclusion that PTGS and TGS are present in the silenced plants. Promoter analysis in silico and using promoter deletion assays predicted that the RCg2 promoter contains a complex region that includes miRNA homologs, MITEs and repetitive sequences. The high frequency of promoter-related silencing suggests functional interactions of these elements of the transgene and the homologous endogenous gene. To identify key elements contributing to the root-preferential expression of RCg2 and the high frequency of silencing observed in transgenic (YXB) lines, several RCg2 promoter deletion constructs were designed. These include 5' deletions MC1, MC2, MC4, MC7 and MC8 and internal deletions MC5, MC11, MC12 and MC13. The frequency with which silencing was encountered in populations of the deletion mutants was used to characterize the effects of various promoter elements. Deletion of the region from -406 to -208 (compared MC11 to YXB, and MC13 to MC1) revealed that region contains a negative element. Among 36 independent transformants, 33% with MC11 expressed GUS and 85% with MC13 showed GUS expression. Comparing MC7 transgenic plants to MC1 revealed that the region ?888 to ?729 is another negative regulatory element, and comparing MC11 to MC12, the proportion of expression of transgenic plants indicated the region ?729 to ?406 is a positive regulatory element.

Aberrant DNA methylation in gene promoters causes gene silencing and is a common event in prostate cancer development and progression. While commonly identified methylated genes have been analyzed for their potential clinical utility in a variety of cancers, few studies have attempted a genome-wide methylation approach to discover new and possibly improved biomarkers for prostate cancer. In order to identify DNA methylation changes associated with aggressive prostate cancer, we performed a genome-wide analysis of 40 prostate cancers using Agilent human CpG island microarrays. Methylation profiles of candidate genes were validated using quantitative MethyLight technology in an independent series of 219 radical prostatectomies and compared to clinicopathological parameters. The effects of methylation on expression of HOXD3 and HOXD8 and the possible role of HOXD8 in progression of PCa were also investigated. We discovered previously unidentified methylation in the HOXD cluster of genes, namely HOXD3 and HOXD8, as well as TGFβ2 and GENE X as potential prognostic biomarkers. Furthermore, unsupervised clustering of samples by methylation signature indicated ERG oncogene expression as significantly different between clusters. Within the independent cohort, we observed strong correlations between Gleason score (GS) and HOXD3 as well as GENE X, while HOXD3 and HOXD8 methylation were associated with ERG expresson. TGFβ2 was an independent predictor of disease recurrence using Cox multivariate regression analysis. In gene expression studies, both HOXD3 and HOXD8 were elevated in cancers with poor prognosis, while DNA methylation did not correlate with expression levels. Both genes were found to contain alternative transcription start sites, explaining the poor correlation between methylation and expression. Finally, knockdown of HOXD8 expression did not have any effect on viable cells or cell motility in an in vitro model. These results indicate that a panel of novel DNA methylation markers distinguish indolent prostate cancers from aggressive ones, and that expression of HOXD3 and HOXD8 is regulated by mechanisms including, but not dependent on, DNA methylation.

Early diagnosis represents an effective way to improve patient prognosis in cancer. New opportunities for cancer diagnosis and screening may arise from identification of cancer-specific epigenetic alterations in the cell-free circulating DNA (cirDNA). This study investigated biomarkers at the level of DNA methylation in the plasma cirDNA of individuals affected with prostate cancer or colorectal cancer. A methylation-sensitive restriction enzyme-based method was used to enrich methylated DNA fractions, which were interrogated on CpG island and human genome tiling microarrays. A number of genes and non-coding loci exhibited differential methylation between prostate cancer patients and controls. The candidate loci identified from these microarray experiments underwent verification by bisulfite modification coupled with pyrosequencing. Our results suggest that microarray-based studies of DNA methylation in the cirDNA can be a promising avenue for the identification of epigenetic biomarkers in cancer.

Early diagnosis represents an effective way to improve patient prognosis in cancer. New opportunities for cancer diagnosis and screening may arise from identification of cancer-specific epigenetic alterations in the cell-free circulating DNA (cirDNA). This study investigated biomarkers at the level of DNA methylation in the plasma cirDNA of individuals affected with prostate cancer or colorectal cancer. A methylation-sensitive restriction enzyme-based method was used to enrich methylated DNA fractions, which were interrogated on CpG island and human genome tiling microarrays. A number of genes and non-coding loci exhibited differential methylation between prostate cancer patients and controls. The candidate loci identified from these microarray experiments underwent verification by bisulfite modification coupled with pyrosequencing. Our results suggest that microarray-based studies of DNA methylation in the cirDNA can be a promising avenue for the identification of epigenetic biomarkers in cancer.

Fetal growth potential reflects a complex regulatory system delivered by genetic and environmental factors acting directly on the fetus or through the placenta. Compromise of this potential, as seen in intrauterine growth restriction (IUGR), is associated with increased perinatal mortality and short and long term morbidity. The expression of several genes has been shown to be disturbed in placentas of fetuses with growth restriction. However, the primary causes for these changes have not yet been elucidated. I proposed that epigenetic mechanisms, specifically DNA methylation, may be involved in placental development leading to modulation of the expression of specific genes, and that their altered regulation will impact fetal development and growth. My primary objective was to identify DNA methylation variation in placenta, in association with variation of gene expression and with poor fetal growth. I used a global genomic screening approach, with 24 selected placental samples, from newborns considered IUGR or normal controls, to identify candidate target genomic regions carrying epigenetic alterations. Candidate regions were followed up, by expression analysis of corresponding regulated genes, for associations with altered expression and by targeted methylation analysis in an expanded cohort of 170 samples, for associations with birthweight percentile. I analyzed methylation variation at imprinting centers (IC), gene promoters and CpG islands. In two genome-wide case control screening studies using distinct commercial microarray platforms I identified approximately 68 differentially methylated autosomal candidate genomic regions overlapping gene promoters. Hypomethylated CpGs mapping to gene promoters were found to be more abundant in placentas of growth restricted newborns than in controls. One of the most interesting candidates, WNT2, was analyzed in an extended sample cohort and showed an association of high promoter methylation to low expression as well as low birthweight percentile. This gene is involved in a pathway that diverts cells from programmed apoptosis. It is highly expressed in placenta, and in mice, targeted biallelic inactivation of Wnt2 has been shown to cause poor growth and perinatal death in 50% of the affected pups. These findings support the hypothesis that dysregulation of epigenetic mechanisms are involved in abnormal placental development and can impact fetal growth.

Fetal growth potential reflects a complex regulatory system delivered by genetic and environmental factors acting directly on the fetus or through the placenta. Compromise of this potential, as seen in intrauterine growth restriction (IUGR), is associated with increased perinatal mortality and short and long term morbidity. The expression of several genes has been shown to be disturbed in placentas of fetuses with growth restriction. However, the primary causes for these changes have not yet been elucidated. I proposed that epigenetic mechanisms, specifically DNA methylation, may be involved in placental development leading to modulation of the expression of specific genes, and that their altered regulation will impact fetal development and growth. My primary objective was to identify DNA methylation variation in placenta, in association with variation of gene expression and with poor fetal growth. I used a global genomic screening approach, with 24 selected placental samples, from newborns considered IUGR or normal controls, to identify candidate target genomic regions carrying epigenetic alterations. Candidate regions were followed up, by expression analysis of corresponding regulated genes, for associations with altered expression and by targeted methylation analysis in an expanded cohort of 170 samples, for associations with birthweight percentile. I analyzed methylation variation at imprinting centers (IC), gene promoters and CpG islands. In two genome-wide case control screening studies using distinct commercial microarray platforms I identified approximately 68 differentially methylated autosomal candidate genomic regions overlapping gene promoters. Hypomethylated CpGs mapping to gene promoters were found to be more abundant in placentas of growth restricted newborns than in controls. One of the most interesting candidates, WNT2, was analyzed in an extended sample cohort and showed an association of high promoter methylation to low expression as well as low birthweight percentile. This gene is involved in a pathway that diverts cells from programmed apoptosis. It is highly expressed in placenta, and in mice, targeted biallelic inactivation of Wnt2 has been shown to cause poor growth and perinatal death in 50% of the affected pups. These findings support the hypothesis that dysregulation of epigenetic mechanisms are involved in abnormal placental development and can impact fetal growth.

Protein arginine methyltransferase, PRMT, is a family of epigenetic enzymes that methylate arginine residues on histone and nonhistone substrates which result in a monomethylation, symmetric dimethylation or asymmetric dimethylation via the transfer of a methyl group from S-adenosyl-L-methionine (SAM). We discovered a novel interaction between two PRMT isoforms: PRMT1 interacts and methylates PRMT6. In this study site-directed mutagenesis was performed on selected arginines identified from tandem mass spectrometric analysis to investigate major methylation sites of PRMT6 by PRMT1. In combination with radiometric methyltransferase assays, we determined two major methylation sites. Methylations at these sites have significant effects on the nascent enzymatic activity of PRMT6 in H4 methylation. PRMTs have the ability to homodimerize which have been linked to methyltransferase activity. We designed dimerization inhibitors (DMIs) to further investigate the need for dimerization for enzyme activity. Preliminary results suggest that the monomeric form of PRMT1 retains methyltransferase activity comparable to that of the uninhibited PRMT1.

<p>Low-dose ionizing radiation (LDIR) exposure (under 10.0 centigray (cGy)) from man-made sources, such as diagnostic imaging, predominates in the US population and comprises nearly 50% of an average individual's yearly radiation exposure (Ullrich, Brooks et al. 2009). The increase in such exposures has led to public and government alarm about the impact of LDIR on human health (Ullrich, Brooks et al. 2009). Besides the mutational effects of radiation exposure, there is concern it might also result in modifications of the epigenome. Such aberrations can disrupt normal development and are involved in the progression of numerous diseases, including cancer (Gasser and Li 2011). High doses of radiation (>100.0 cGy) have been shown to cause epigenetic disruption (Kaup, Grandjean et al. 2006; Tamminga, Koturbash et al. 2008; Ilnytskyy, Koturbash et al. 2009), which is necessary for the persistence of radiation-induced genomic instability (Rugo, Mutamba et al. 2011); however, it is presently unclear to what extent LDIR in vivo alters the epigenome. </p><p>The viable yellow agouti (Avy) mouse was used here to characterize the dose-dependent epigenetic response to LDIR. The Avy mouse is a unique biological model that functions as a biosensor for environmentally induced epigenetic changes and disease susceptibility due to the presence of a metastable epiallele that modulates coat color (Waterland and Jirtle 2003). Pregnant dams were whole-body exposed to one of five doses of X-ray radiation ranging from 0-10.0 cGy on gestational day 4.5. Using a phantom mouse model, the intrauterine doses were estimated to be 0.0 cGy, 0.4 cGy, 0.7 cGy, 1.4 cGy, 3.0 cGy, and 7.6 cGy, respectively. At weaning, offspring coat colors were assessed and tissues were collected for methylation analysis. First, methylation changes at CpG sites in the Avy and Cdk activator binding protein (CabpIAP) metastable epialleles and at intracisternal a particle (IAP) elements across the genome were quantified using Sequenom technology. Second, three imprinted genes, Peg3, Nnat, and H19, were assessed for methylation changes in differentially methylated regions (DMRs) that regulate their parent-of-origin monoallelic expression using Sequenom technology. Lastly, it was postulated that the epigenetic changes at the Avy locus could be counteracted with dietary alterations. To test this hypothesis, female mice were placed on an antioxidant-supplemented diet prior to pregnancy and throughout gestation and lactation. Pregnant dams were irradiated with 3.0 cGy of whole-body X-rays. Offspring coat colors were assessed and methylation changes at the Avy allele were measured with the Sequenom platform. </p><p>Herein, I demonstrate that in utero LDIR exposure induced epigenetic changes in the Avy mouse in a dose-dependent and sex-specific manner. Acute, whole-body exposure to 0.7 cGy, 1.4 cGy, 3.0 cGy or 7.6 cGy X-rays significantly shifted offspring coat color distribution toward pseudoagouti. Acute exposure to 1.4 cGy, 3.0 cGy, and 7.6 cGy significantly increased methylation at multiple CpG sites in the Avy metastable epiallele in male offspring, but not female offspring. Methylation changes at DMRs in Nnat, Peg3, and H19 also occurred in a dose-dependent manner. Furthermore, inhibition of the phenotypic and Avy methylation changes with an antioxidant-supplemented diet suggests that the mechanisms to induce epigenetic changes are mediated by oxidative stress. These results demonstrate that relevant, low doses of radiation can elicit epigenetic changes that lead to a persistent phenotype, but can be mitigated with dietary supplementation. The successful completion of this project has resulted in the first in vivo epigenetic characterization of LDIR exposure and will contribute to the development of more relevant risk assessment strategies for protecting human populations.</p> / Dissertation

No description available.

The interactions of sulfate-reducing bacteria and Spartina alterniflora marsh grass have been established using a simulated salt marsh system and these interactions have been quantified using geochemical and molecular tools. Plant activities have a direct influence on mercury methylators and therefore control mercury transformation in the environment. Biogeochemical data show that sulfate and sulfide profiles change seasonally due to plant growth and senescence. Spartina alterniflora impact the two drivers for sulfate and sulfide transformation. The community of sulfate-reducing bacteria serve as the anaerobic driver and transform sulfate to sulfide (sulfate reduction). Sulfate-reducing bacteria have been identified as the principal methylators of mercury (Andersson, et al., 1990; Compeau and Bartha, 1985; Compeau and Bartha, 1984; Blum and Bartha, 1980; Gilmour and Capone). The aerobic driver is dissolved oxygen present in both porewater and plant root exudates, which transform sulfide back to sulfate (sulfide oxidation). Sulfate is not limiting in the vegetated sediment, even at the lower depths. Therefore, although sulfate reduction rates were high when plant activity was high, oxidative processes were also significant in the upper 4-cm of the sediment. In addition, demethylation of methylmercury to ionic Hg(II) in the porewater can occur through oxidative processes (Oremland et al., 1991). Therefore, the significance of sulfide oxidation may have strong implications for methylmercury demethylation in our marsh system.